Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Keratosis, Actinic 3Pancreatic Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis 1High-grade Anal Intraepithelial Neoplasia 1Dermatitis, Contact 1Condylomata Acuminata 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Breast Cancer Lymphedema 1

Interventions

Carboplatin 341Paclitaxel 262Cisplatin 233Pemetrexed 226Docetaxel 206Erlotinib Hydrochloride 193Gemcitabine 178pembrolizumab 137Bevacizumab 121Radiotherapy 118Nivolumab 84Gefitinib 73Vinorelbine 64Cetuximab 58atezolizumab 47Afatinib 46durvalumab 44osimertinib 41Radiosurgery 35Ipilimumab 34Drug Therapy 32Taxes 30Albumin-Bound Paclitaxel 29130-nm albumin-bound paclitaxel 29Surgical Procedures, Operative 28Etoposide 25Irinotecan 24Sorafenib 21Cyclophosphamide 20Radiation 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Carcinoma, Non-Small-Cell Lung × Ointments × Clear all
NCT01593995 2014-11-04

EGF Ointment for Erlotinib Skin Lesion

Dong-A University Hospital

Phase 2 Completed
52 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡